A phase I study of OX382

Trial Profile

A phase I study of OX382

Planning
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs OX382 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2017 According to an Orexo media release, this trial is scheduled to start in the first quarter of 2018.
    • 13 Jul 2017 New trial record
    • 11 Jul 2017 According to an Orexo media release, the company is planning to initiate this study within the next 6 to 9 months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top